Lymphomas are a diverse group of cancers of the immune system, which is the body’s primary defense against autoimmune disease, infections, and malignancy.
Now, researchers at the University of Tsukuba have clarified risk factors and molecular mechanisms underlying primary and adaptive resistance to cancer immunotherapy. This knowledge may inform treatment strategies against aggressive Non-Hodgkin lymphomas (NHL) including Burkitt lymphoma and diffuse large B-cell lymphoma.
